TrialWorld journal of urology2020

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.

Neal Shore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.